Dataset Information

Progress towards Adjuvant Development: Focus on Antiviral Therapy.

ABSTRACT: In recent decades, vaccines have been extraordinary resources to prevent pathogen diffusion and cancer. Even if they can be formed by a single antigen, the addition of one or more adjuvants represents the key to enhance the response of the immune signal to the antigen, thus accelerating and increasing the duration and the potency of the protective effect. Their use is of particular importance for vulnerable populations, such as the elderly or immunocompromised people. Despite their importance, only in the last forty years has the search for novel adjuvants increased, with the discovery of novel classes of immune potentiators and immunomodulators. Due to the complexity of the cascades involved in immune signal activation, their mechanism of action remains poorly understood, even if significant discovery has been recently made thanks to recombinant technology and metabolomics. This review focuses on the classes of adjuvants under research, recent mechanism of action studies, as well as nanodelivery systems and novel classes of adjuvants that can be chemically manipulated to create novel small molecule adjuvants.

SUBMITTER: Brai A

PROVIDER: S-EPMC10253057 | biostudies-literature | 2023 May

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Progress towards Adjuvant Development: Focus on Antiviral Therapy.

Brai Annalaura A Poggialini Federica F Pasqualini Claudia C Trivisani Claudia Immacolata CI Vagaggini Chiara C Dreassi Elena E

International journal of molecular sciences 20230525 11

In recent decades, vaccines have been extraordinary resources to prevent pathogen diffusion and cancer. Even if they can be formed by a single antigen, the addition of one or more adjuvants represents the key to enhance the response of the immune signal to the antigen, thus accelerating and increasing the duration and the potency of the protective effect. Their use is of particular importance for vulnerable populations, such as the elderly or immunocompromised people. Despite their importance, o ...[more]

PMID: 37298177

Similar Datasets

Project description:Dr. John Herrick described the first clinical case of sickle cell anaemia (SCA) in the United States in 1910. Subsequently, four decades later, Ingram and colleagues characterized the A to T substitution in DNA producing the GAG to GTG codon and replacement of glutamic acid with valine in the sixth position of the βS -globin chain. The establishment of Comprehensive Sickle Cell Centers in the United States in the 1970s was an important milestone in the development of treatment strategies and describing the natural history of sickle cell disease (SCD) comprised of genotypes including homozygous haemoglobin SS (HbSS), HbSβ0 thalassaemia, HbSC and HbSβ+ thalassaemia, among others. Early drug studies demonstrating effective treatments of HbSS and HbSβ0 thalassaemia, stimulated clinical trials to develop disease-specific therapies to induce fetal haemoglobin due to its ability to block HbS polymerization. Subsequently, hydroxycarbamide proved efficacious in adults with SCA and was Food and Drug Administration (FDA)-approved in 1998. After two decades of hydroxycarbamide use for SCD, there continues to be limited clinical acceptance of this chemotherapy drug, providing the impetus for investigators and pharmaceutical companies to develop non-chemotherapy agents. Investigative efforts to determine the role of events downstream of deoxy-HbS polymerization, such as endothelial cell activation, cellular adhesion, chronic inflammation, intravascular haemolysis and nitric oxide scavenging, have expanded drug targets which reverse the pathophysiology of SCD. After two decades of slow progress in the field, since 2018 three new drugs were FDA-approved for SCA, but research efforts to develop treatments continue. Currently over 30 treatment intervention trials are in progress to investigate a wide range of agents acting by complementary mechanisms, providing the rationale for ushering in the age of effective and safe combination drug therapy for SCD. Parallel efforts to develop curative therapies using haematopoietic stem cell transplant and gene therapy provide individuals with SCD multiple treatment options. We will discuss progress made towards drug development and potential combination drug therapy for SCD with the standard of care hydroxycarbamide.

Project description:Diabetes results from insufficient production of the hormone insulin from beta cells in pancreatic islets. Islet transplantation can replace the lost beta cells in patients but is limited by the scarcity of available donor organs. Our aim is to differentiate pluripotent stem cells into functional islets that can serve as an unlimited source for transplantation to treat diabetes. We have investigated the therapeutic potential of pancreatic endoderm cells derived from human embryonic stem cells. Several weeks following transplant into diabetic rodents, these cells mature and secrete sufficient human insulin, in a regulated manner, to reverse diabetes. In rats, we observed inconsistent survival of pancreatic endoderm cells implanted subcutaneously in macroencapsulation devices designed to be immunoprotective via use of a cell impermeable layer, but this was rectified by the addition of portals designed to enable direct capillary vascular permeation into the device interior. In contrast both device types supported cell survival, differentiation and function in mice, with more rapid C-peptide release and better glucose tolerance observed using the devices containing portals. Kidney capsule grafts often contained ductal cells and cysts, whereas cells implanted subcutaneously within macroencapsulation devices differentiated predominantly to endocrine cells. In collaboration with Aspect Biosystems, we are also exploring the feasibility of using 3D bioprinting as an approach to both contain implanted islet cells and protect them from immune attack. As part of a ViaCyte clinical trial (clinicaltrial.gov identifier: NCT03163511), we investigated the safety and efficacy of pancreatic endoderm cells implanted in nonimmunoprotective macroencapsulation devices for the treatment of patients with type 1 diabetes and hypoglycemic unawareness. Patients underwent subcutaneous implant of cell products combined with an immunosuppressive regimen. After implant, patients had increased fasting Cpeptide levels, increased glucose-responsive C-peptide levels, and developed mixed meal-stimulated C-peptide secretion. Patients had reduced insulin requirements, increased time in target blood glucose range, and improved hypoglycemic awareness. Explanted grafts contained cells with a mature beta cell phenotype that were immunoreactive for insulin, islet amyloid polypeptide, and MAFA. Collectively, these findings support future investigation into optimizing cell therapies for diabetes.

Dataset Information

Progress towards Adjuvant Development: Focus on Antiviral Therapy.

Publications

Progress towards Adjuvant Development: Focus on Antiviral Therapy.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets